How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,320 results for

Instilling Eye Drops

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Clinical Effects of Diquas-S for Patients With Dry Eye After Cataract Surgery

, dryness, burning sensation, and foreign body sensation. The reasons of dry eye (DE) development after cataract surgery include thermal and light toxicity from the microscope, corneal epithelial damage, and frequent irrigation of ocular surface during operation, sterilization of conjunctival sac and eyelid with chemicals, transection of the corneal nerves by corneal incision, use of topical anesthetics, and preservatives in topical eye drops. In this era of high expectation of patients and premium (...) tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks. Active Comparator: Preservative containing diquafosol group The subjects

2018 Clinical Trials

102. Eyelash Prostheses Compared to 5.0% Lifitegrast BID for Dry Eye Disease.

% Lifitegrast Ophthalmic Solution 5.0% Lifitegrast Ophthalmic Solution Outcome Measures Go to Primary Outcome Measures : Non-inferior change from baseline in tear break up time as measured by the Oculus Keratograph in the interventional subjects compared to the active control subjects [ Time Frame: The primary endpoint will be assessed 3 weeks after eyelash prosthesis placement in the interventional arm and 5 weeks after initiation of eye drops in the active comparator arm ] A non-inferiority endpoint (...) in tear break up time Secondary Outcome Measures : Non-inferior change in tear meniscus height as measured by the Oculus Keratograph in the treatment subjects compared to control subjects [ Time Frame: The secondary endpoint will be assessed 3 weeks after eyelash prosthesis placement in the interventional arm and the interventional arm and 5 weeks after initiation of eye drops in the active comparator arm ] Non-inferiority endpoint in tear meniscus height Non-inferior change from baseline in SPEED II

2018 Clinical Trials

103. Immediate effect of a tear enhancer and meibomian gland expression on the corneal surface and whole eye higher order aberrations Full Text available with Trip Pro

subjects (25 females, mean age±sd 32.5±11.0 years, and 25 males, 33.88±11.2 years) for two pupil sizes (3 and 6mm) in a dark environment. One drop of Blink Contacts™ (Abbott Medical Optics) was instilled into the right eye and HOA measurements repeated after 30s. After 1h, the meibomian glands of the left lower eyelid were gently squeezed and HOA measurements repeated after 30s.There was no significant difference for CS and WE root mean square (RMS) HOAs between right and left eyes before (both pupil (...) Immediate effect of a tear enhancer and meibomian gland expression on the corneal surface and whole eye higher order aberrations To investigate changes in higher order ocular aberrations (HOA) induced by the administration of 0.15% sodium hyaluronate tear enhancer (TE) and meibomian gland expression (ME) on the tear film of normal subjects.HOA values were obtained from the corneal surface (CS) and whole eye (WE), using a corneal topographer and Shack-Hartmann aberrometer, from both eyes of 50

2018 Journal of optometry

104. Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction Full Text available with Trip Pro

Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction To investigate the efficacy of combined topical 0.05% cyclosporine A (CsA; Restasis®, Allergan pharmaceuticals, USA) and 0.1% sodium hyaluronate treatment in dry eyes with meibomian gland dysfunction (MGD).In a retrospective analysis, 53 patients (106 eyes) with MGD were enrolled and performed lid warm massage for 10min daily and be instilled preservative free (...) sodium hyaluronate 0.1% eye drops 4 times daily. Patients were divided into subjects treated with topical 0.05% CsA and preservative free sodium hyaluronate vehicle (experimental group, n=74 eyes) and subjects treated with the preservative free sodium hyaluronate vehicle (control group, n=32 eyes). They were evaluated at baseline and 1, 2, and 3mo for subjective symptoms and objective signs including tear film break-up time (tBUT), Schirmer test, corneal staining (CS) score, lid margin telangiectasia

2018 International journal of ophthalmology Controlled trial quality: uncertain

105. Effect of Hyaluronic Acid/Trehalose in Two Different Formulations on Signs and Symptoms in Patients with Moderate to Severe Dry Eye Disease Full Text available with Trip Pro

decreased, and tear breakup time (BUT) increased for both groups (p < 0.001 each). Mean instillation frequency was 3.1 ± 2.6 drops/day when using HT and 1.9 ± 2.2 drops/day when using HTC-gel (p=0.02). A significant improvement in the quality of sleep was observed with both treatments (p=0.01).Our results show improvement in signs and symptoms of DED in both groups. While instillation of HTC-gel resulted in a lower instillation frequency, both formulations of trehalose showed good clinical efficacy (...) Effect of Hyaluronic Acid/Trehalose in Two Different Formulations on Signs and Symptoms in Patients with Moderate to Severe Dry Eye Disease This randomized, observer-masked, crossover study investigated the effect of two hyaluronic acid/trehalose-based containing formulations, with different physical properties, on the signs and symptoms in patients with moderate to severe dry eye disease (DED).In one group, patients received a mixture of sodium hyaluronate and trehalose (HT, Thealoz Duo®

2018 Journal of ophthalmology Controlled trial quality: uncertain

106. Management of post-LASIK dry eye: a multicenter randomized comparison of a new multi-ingredient artificial tear to carboxymethylcellulose Full Text available with Trip Pro

).This was a double-masked, randomized, parallel-group study conducted in 14 clinical centers in Canada and Australia. Subjects with no more than mild dry eye instilled CMC-HA or CMC for 90 days post-LASIK. Ocular Surface Disease Index© (OSDI; primary efficacy measure), corneal staining, tear break-up time (TBUT), Schirmer's test, acceptability/tolerability surveys, and visual acuity were assessed at screening and days 2, 10, 30, 60, and 90 post-surgery. Safety analyses included all enrolled.A total of 148 (...) , reaching statistical significance at day 30 (P=0.013). Both treatments were well tolerated.CMC-HA-containing artificial tears relieved post-LASIK ocular dryness as well as CMC alone, and demonstrated incremental benefit in uncorrected vision, with a favorable safety profile. Results support use of CMC-HA eye drops to reduce signs and symptoms of ocular dryness post-LASIK.

2018 Clinical ophthalmology (Auckland, N.Z.) Controlled trial quality: uncertain

107. Flicker electroretinograms of eyes with cataract recorded with RETeval system before and after mydriasis Full Text available with Trip Pro

Flicker electroretinograms of eyes with cataract recorded with RETeval system before and after mydriasis The aim of this study is to determine the effect of pupil size of eyes with cataracts on the flicker electroretinograms (ERGs) elicited and recorded with the RETeval system.Forty-one eyes of 41 patients (mean age, 76.5±7.3 years) that had grade 2 nuclear or cortical cataract without any other abnormalities were studied. Flicker ERGs were recorded before and after mydriatic drops instillation (...) ). The mean amplitudes and implicit times of the nuclear and cortical cataracts groups before the mydriasis were also not significantly different from those after mydriasis for all stimulus intensities.The lack of significant differences in the amplitudes and the implicit times of the flicker ERG of cataractous eyes before and after mydriasis indicated that the RETeval flicker ERGs in cataractous eyes is less affected by the pupil diameter. With our earlier study, it was assumed that the effect

2018 Clinical ophthalmology (Auckland, N.Z.)

108. Study of Efficacy and Tolerability of SYSTANE Complete in Patients With Dry Eye Disease

using fluorescein, an ocular staining dye Secondary Outcome Measures : Change from baseline in dry eye symptom score at Day 1 [ Time Frame: Baseline, Day 1 ] As reported by the patient using a Likert scale post drop instillation Soothing sensation score [ Time Frame: Day 1 ] As reported by the patient using a Likert scale post drop instillation Tolerability assessment score [ Time Frame: Day 1 ] As reported by the patient using an assessment questionnaire post drop instillation Change from baseline (...) /treatment Experimental: SYSTANE Complete Propylene glycol-based eye drops, 1 drop in each eye twice a day (BID) (morning and evening) for 28 days. Patients can administer additional doses in between the scheduled daily doses as needed Other: Propylene glycol-based eye drops Nano-emulsion ocular lubricant Other Name: SYSTANE® Complete Outcome Measures Go to Primary Outcome Measures : Change from baseline in Tear Film Break-up Time (TFBUT) at Day 14 [ Time Frame: Baseline, Day 14 ] TFBUT will be assessed

2018 Clinical Trials

109. REMOGEN® Omega Versus Cationorm® in the Treatment of Patients Suffering From Dry Eye

and Interventions Go to Arm Intervention/treatment Experimental: Remogen Device: Remogen instil 1 drop of the product in each eye, 4 times per day Active Comparator: Cationorm Device: Cationorm instil 1 drop of the product in each eye, 4 times per day Outcome Measures Go to Primary Outcome Measures : OSSF [ Time Frame: Day 28 ] Ocular surface staining with fluorescein (OSSF) Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal (...) REMOGEN® Omega Versus Cationorm® in the Treatment of Patients Suffering From Dry Eye REMOGEN® Omega Versus Cationorm® in the Treatment of Patients Suffering From Dry Eye - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2018 Clinical Trials

110. Crosslinked Hyaluronic Acid With Liposomes and Crocin in Dry Eye

in a multi-dose container, it does not contain a preservative due to the dispenser that does not let microorganisms from outside. Contact lenses can be used while both lubricants are applied. In this regard, the study patients used their silicone hydrogel contact lenses monthly during the study. All patients in the study had a period of one month without using any type of artificial tear or eye drops. Once this time or study was over, the patients were explained how artificial tears should be instilled (...) of Seville Study Details Study Description Go to Brief Summary: A total of 50 eyes were analyzed (25 patients). The subjects selected were over 18 years of age. No gender distinction was made in the choice of subjects. All subjects were carriers of silicone hydrogel contact lenses. The antecedents of the eye diseases not identified, neither the previous eye surgeries nor the systemic or ocular medication. All patients read, understood and signed an informed consent form of the study. Condition or disease

2018 Clinical Trials

111. Low concentration of sodium hyaluronate temporarily elevates the tear film lipid layer thickness in dry eye patients with lipid deficiency Full Text available with Trip Pro

% or 0.3% sodium hyaluronate (SH) eye drops by using the LipiView ocular surface interferometer.In the lipid deficiency group, the LLT increased from baseline at 1min post instillation. The LLT after the instillation of 0.1% SH was significantly higher than that after the instillation of 0.3% SH (P<0.001). The LLT returned to baseline at 15min post instillation of 0.1% SH and at 5min post instillation of 0.3% SH. In the non-lipid deficiency group, the LLT decreased from baseline at 1min and returned (...) Low concentration of sodium hyaluronate temporarily elevates the tear film lipid layer thickness in dry eye patients with lipid deficiency To investigate the effects of different concentrations of artificial tears on lipid layer thickness (LLT) and blink rate (BR) in dry eye patients.This study included 106 eyes of 58 patients with dry eye. The lipid deficiency type was defined as the LLT baseline <75 nm. The LLT and BR were measured at baseline and 1, 5 and 15min after the instillation of 0.1

2018 International journal of ophthalmology

112. Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye

Lacrimal Apparatus Diseases Drug: Autologous Serum 20% Drug: Autologous Serum 50% Phase 3 Detailed Description: To determine the difference between autologous serum 20% vs 50%, in terms of improvement of symptoms, improvement of ocular surface parameters and acceptable tolerability in patients with severe dry eye syndrome. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 20 participants Allocation: Randomized Intervention Model (...) Active Comparator: Autologous Serum 20% Treatment with Autologous Serum 20% for 2 months Drug: Autologous Serum 20% Instillation of 1 drop of Autologous Serum 20% four times a day Other Name: Autologus serum low concentration Active Comparator: Autologous Serum 50% Treatment with Autologous Serum 50% for 2 months Drug: Autologous Serum 50% Instillation of 1 drop of Autologous Serum 50% four times a day Other Name: Autologus serum high concentration Outcome Measures Go to Primary Outcome Measures

2018 Clinical Trials

113. Use of 5.0% Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease in Contact Lens Wearers

, the investigators may be able to relieve some of that discomfort. This study will enroll 50 subjects with contact lens discomfort and will receive lifitegrast to use over a period of approximately 3 months. Condition or disease Intervention/treatment Phase Contact Lens Dry Eye Drug: Lifitegrast Phase 4 Detailed Description: The most common reason for contact lens drop out is ocular discomfort, with patients identifying dryness as the major reason. Currently, many patients with contact lens dry eye (CLDE (...) Experimental: Treatment lifitegrast ophthalmic solution 5.0%, to be instilled 1 drop in each eye, twice a day Drug: Lifitegrast Eye drop Other Name: Xiidra Outcome Measures Go to Primary Outcome Measures : Number of hours related to comfort in wearing contact lenses. [ Time Frame: Baseline to Week 12. ] The amount of comfortable lens wear time averaged over the 12th week of lens wear as reported with participant diary. Secondary Outcome Measures : Number of hours related to comfort in wearing contact

2018 Clinical Trials

114. A Controlled, Randomized Double-Blind Study to Evaluate the Safety and Efficacy of Chitosan-N-Acetylcysteine for the Treatment of Dry Eye Syndrome. (Abstract)

A Controlled, Randomized Double-Blind Study to Evaluate the Safety and Efficacy of Chitosan-N-Acetylcysteine for the Treatment of Dry Eye Syndrome. This study was designed to evaluate the effect of chitosan-N-acetylcysteine (C-NAC) eye drops on tear film thickness (TFT) in patients with dry eye syndrome (DES).This was a controlled, randomized, double-blind clinical investigation with patients assigned to 2 cohorts. In Cohort I, 21 patients were randomized to receive 1 instillation of C-NAC eye (...) drops in 1 eye and placebo (normal saline solution) in the contralateral eye. In Cohort II, 17 patients were randomized to receive C-NAC eye drops once (QD) or twice (BID) daily for 5 days. TFT was assessed with a custom-built ultrahigh-resolution optical coherence tomography system.In Cohort I, mean TFT increased from 3.9 ± 0.5 μm predose to 4.8 ± 1.1 μm 10 min postdose after treatment with C-NAC. The increase was significantly different from placebo over time (P < 0.0001) and remained stable until

2018 Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics Controlled trial quality: uncertain

115. Kinetics of γ-cyclodextrin nanoparticle suspension eye drops in tear fluid. (Abstract)

Kinetics of γ-cyclodextrin nanoparticle suspension eye drops in tear fluid. We have developed nanoparticle γ-cyclodextrin dexamethasone (DexNP) and dorzolamide (DorzNP) eye drops that provide sustained high drug concentrations on the eye surface. To test these characteristics, we measured dexamethasone and dorzolamide levels in tear fluid in humans following eye drop administration.Concentration of dexamethasone was measured by mass spectrometry. One drop of DexNP was instilled into one eye (...) . Tear fluid was sampled with microcapillary pipettes at seven time-points after drop instillation. Control eyes received Maxidex(®) (dexamethasone). The same procedure was performed for dorzolamide with DorzNP and Trusopt(®) .Six subjects were included in each group. The peak concentration (μg/ml ± standard deviation) of dexamethasone for DexNP eye drops (636.6 ± 399.1) was up to 19-fold higher than with Maxidex(®) (39.3 ± 18.9) (p < 0.001). At 4 hr, DexNP was still 10 times higher than Maxidex(®

2014 Acta ophthalmologica Controlled trial quality: uncertain

116. Clinical Evaluation of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections in Subjects with Neovascular Age-Related Macular Degeneration. (Abstract)

AMD was previously managed by anti-vascular endothelial growth factor intravitreal injections.Treatments administered for 52 weeks included placebo eye drops instilled 4 times daily (n=73); pazopanib 5 mg/ml instilled 3 (n=72) or 4 times daily (n=74); pazopanib 10 mg/ml instilled 2 (n=73), 3 (n=73), or 4 times daily (n=72); or ranibizumab injection administered once every 4 weeks (n=73). In addition, for all eye drop treatment groups, open-label ranibizumab was administered as needed.The main (...) of pazopanib in plasma seemed to be reached by week 4. The most common ocular adverse events related to pazopanib and ranibizumab were application site pain (3%) and injection site hemorrhage (1%), respectively. No treatment-related serious adverse events were reported.Pazopanib was well tolerated. Daily pazopanib eye drops in neovascular AMD subjects did not result in therapeutic benefit beyond that obtained with ranibizumab alone.Copyright © 2015 American Academy of Ophthalmology. Published by Elsevier

2014 Ophthalmology Controlled trial quality: predicted high

117. Comparison of preservative-free ketotifen fumarate and preserved olopatadine hydrochloride eye drops in the treatment of moderate to severe seasonal allergic conjunctivitis. (Abstract)

and presenting with moderate to severe itching and conjunctival hyperemia. Eligible patients initiated either ketotifen or olopatadine treatment at a dose of one drop twice daily for 28days. The resolution of ocular signs and symptoms was assessed on day 7 and day 28. Itching was also assessed within 15minutes following the first instillation (day 0). Conjunctival impression cytology was performed at each visit to assess the evolution of ICAM-1 expression (day 0, 7 and 28).Seventy-five patients were (...) Comparison of preservative-free ketotifen fumarate and preserved olopatadine hydrochloride eye drops in the treatment of moderate to severe seasonal allergic conjunctivitis. To compare preservative-free ketotifen 0.025% ophthalmic solution to olopatadine 0.1% ophthalmic solution in with the treatment of seasonal allergic conjunctivitis (SAC) in clinical practice.This was a comparative, randomised, investigator-masked, pilot clinical study in adult patients with documented history of SAC

2014 Journal français d'ophtalmologie Controlled trial quality: uncertain

118. CLINICAL EVALUATION OF PAZOPANIB EYE DROPS IN HEALTHY SUBJECTS AND IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. (Abstract)

CLINICAL EVALUATION OF PAZOPANIB EYE DROPS IN HEALTHY SUBJECTS AND IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. To evaluate pazopanib 10 mg/mL eye drops (pazopanib) in healthy subjects and in subjects with previously untreated subfoveal choroidal neovascularization secondary to age-related macular degeneration.Study 1 (single center, randomized, placebo-controlled, double-masked) included 3 cohorts of 12 to 13 healthy subjects each who instilled pazopanib or placebo 4 times (...) ) (primary endpoint), retinal morphology, choroidal neovascularization size, or total lesion size. Complement Factor H genotype had no effect on changes from baseline in the best-corrected visual acuity or central retinal thickness. The most common pazopanib-related ocular adverse events included eye irritation (Study 1, n = 7) and instillation site pain (Study 2, n = 3). No serious adverse events were reported.Pazopanib was well tolerated. In subjects with previously untreated neovascular age-related

2014 Retina (Philadelphia, Pa.) Controlled trial quality: uncertain

119. Tropicamide 1% mydriatic effect: comparison between spray in closed eyes and eye drops in open eyes. (Abstract)

Tropicamide 1% mydriatic effect: comparison between spray in closed eyes and eye drops in open eyes. The aim of this study was to evaluate by serial measurements, pupil mydriasis produced by topical application of tropicamide 1% using a spray in a closed eye or instillation in an open eye in adult and elderly populations.The research was done from February to April of 2011 in the Policlinica Ronaldo Gazolla, located in the Arcos da Lapa Campus of Estacio de Sá University, RJ- Brazil (...) . It was a clinical trial, controlled and randomized, made in a series of 50 patients that were being prepared for ophthalmoscopy examination. They were submitted to eye drop administration of 1% tropicamide in an open eye and to eyelid margin vaporization in a closed eye. The eyes were chosen for the administration of drops or spray according to a pseudo-random numbers table from Excel (2007) before application. The pupil diameter was measured before instillation and after 10, 20, and 30 min in both eyes

2012 Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics Controlled trial quality: uncertain

120. Efficacy of Mydriatic Drops in Premature Infants

: Drug used in the examination of premature infants. to investigate side effects of eye drops used Other Name: Tropicamide and mydfline used Outcome Measures Go to Primary Outcome Measures : The mean pupillary diameter [ Time Frame: an average of 1 year ] will be measured with a ruler after 60 minutes instillation of mydriatic Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor (...) Summary: Because of the neonatologists reported that some infants had suffered from vomiting, bradycardia, hypotonia, and aspiration risk about 30-60 minutes after the fundus examination in the intensive care unit. The investigators observed the pupil dilation effects and side effects of tipple instillation of phenylephrine 2.5% plus tropicamide 0.5% ophthalmic drop combination which the investigators routinely used in ROP examination. Condition or disease Intervention/treatment Retinopathy

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>